focus -WSS

focus

author：entertainment 2025-08-26 10:52:28 - browse：2

Americans who suffer severe allergic reactions won’t have alternatives to auto-injectors like the EpiPen for a while longer. In a surprise move, the Food and Drug Administration on Tuesday declined to approve neffy, an epinephrine nasal spray. Instead, the FDA asked the drug’s manufacturer, ARS Pharma, to conduct further studies, specifically comparing the effect of repeat doses of epinephrine administered via nasal spray versus auto-injection in people with allergic rhinitis, or hay fever.

This was unexpected, and disappointing, for ARS Pharma: In May, an FDA advisory committee had voted 16-6 in favor of neffy’s approval for adults, and 17-5 in favor for children. But there is at least one party that’s likely to benefit from this development: Viatris, the maker of EpiPen, the brand-name epinephrine auto-injector used to treat anaphylaxis. (A generic version is also available, made by Teva).

In June, Viatris filed a citizen petition with the FDA, saying that the available evidence left doubts about how neffy would actually perform in a real-life anaphylactic event compared to auto-injectable epinephrine.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： What will save rural psychiatry services? Higher Medicaid payments

WSS

The Sacklers, horror, and ‘The Fall of the House of Usher’

Latest bird flu infection made farmworker sicker than earlier cases

Average age of first period drops to 11.9 years, study shows

Will General Catalyst be the first of many hospital takeovers?

Biotech incubator Curie.Bio graduates its first startup

Abortion clinic in Cancun will cater to Americans

explore

focus

knowledge

Malaria cases in Florida and Texas: Here’s what you need to know

Just how powerful is the placebo effect?

State Dept. review finds Biden bears some blame for Afghanistan failures

HPV cancer vaccine study demonstrates efficacy

State Dept. review finds Biden bears some blame for Afghanistan failures

Lab trade group sues FDA to halt regulation of lab

Hollywood unions extend contract negotiations for actors

Excited delirium, Elijah McClain, and emergency physicians

Medical records are filled with copy

Sanofi CEO defends move to abandon profit guidance, boost research

leisure time

Startling documents reveal new facets of Sacklers' opioid empire

Addiction doctors spar with methadone clinics over legislation

The new shift in health care is toward less care

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

The new shift in health care is toward less care

White House calls on federal agencies to crack down on AI abuses

focus

focus

focus

hotspot